HEART FAILURE — GENETIC RISK

Heart Failure Genetic Risk — cardiomyopathy is the leading cause of heart failure in young adults, and approximately 30-50% has a genetic cause where the specific gene determines whether early ICD placement, disease-specific therapy, or family screening is needed.

Whole genome sequencing evaluates all cardiomyopathy and heart failure genes — TTN, LMNA, MYH7, MYBPC3, SCN5A, RBM20, FLNC, DES, PLN — providing the gene-specific diagnosis that guides ICD decisions, therapy selection, and family cascade screening.

TTN
LMNA
MYH7
MYBPC3
SCN5A
RBM20
FLNC
PLN

About this condition

Heart Failure — Genetic Risk

Heart failure affects approximately 6.7 million American adults, with cardiomyopathy as a leading cause — particularly in younger patients. Approximately 30-50% of dilated cardiomyopathy (DCM) and up to 60% of hypertrophic cardiomyopathy (HCM) has an identifiable genetic cause. TTN truncation variants (TTNtv) are the most common genetic cause of DCM, accounting for approximately 20-25% of familial DCM. Other key DCM genes include LMNA (lamin A/C — 5-10% of familial DCM), MYH7, MYBPC3, TNNT2, RBM20, FLNC, DES, and PLN. HCM is caused primarily by MYH7 and MYBPC3 (together ~70% of genotype-positive HCM).

Gene-specific heart failure management is increasingly well-defined. LMNA variants confer high arrhythmic risk disproportionate to the degree of ventricular dysfunction — standard heart failure guidelines (which recommend ICD at LVEF ≤35%) are INSUFFICIENT for LMNA-DCM, where sudden cardiac death can occur with preserved or mildly reduced LVEF. European guidelines recommend ICD implantation in LMNA-DCM at LVEF ≤45% with additional risk factors. FLNC truncation variants also carry high arrhythmic risk with specific surveillance implications. PLN (phospholamban) R14del is associated with arrhythmogenic cardiomyopathy requiring early ICD.

Beyond device decisions, genetic diagnosis of cardiomyopathy enables family cascade screening — identifying first-degree relatives at 50% risk who benefit from cardiac surveillance (echocardiography, ECG, cardiac MRI) before symptoms develop. Presymptomatic identification allows initiation of neurohormonal therapy (ACE inhibitors/ARBs, beta-blockers) when early ventricular dysfunction is detected — before clinical heart failure develops. Mavacamten (Camzyos), a cardiac myosin inhibitor, is FDA-approved specifically for obstructive HCM — a gene-specific targeted therapy.

LMNA-DCM patients die of sudden cardiac death at LVEF >35% — the threshold where standard guidelines recommend ICD. Gene-specific LMNA guidelines lower the ICD threshold to prevent these deaths. Without molecular diagnosis, LMNA patients don't receive appropriately early ICDs.

Gene locus: TTN (2q31.2), LMNA (1q22), MYH7 (14q11.2), MYBPC3 (11p11.2), SCN5A (3p22.2), RBM20 (10q25.2), FLNC (7q32.1), PLN (6q22.31)

Standard heart failure guidelines use LVEF <35% for ICD decisions. LMNA patients die at LVEF 40-50%. Gene-specific management saves lives by lowering intervention thresholds for high-risk genotypes.

LMNA-DCM requires ICD at higher LVEF than standard guidelines — molecular diagnosis prevents sudden cardiac death

Multiple studies demonstrate that LMNA-DCM has a malignant arrhythmic phenotype — ventricular tachycardia and sudden cardiac death can occur when LVEF is only mildly reduced (40-50%). The standard heart failure ICD threshold of LVEF ≤35% would leave these patients unprotected. European guidelines now recommend ICD consideration in LMNA-DCM at LVEF ≤45% with additional risk factors (NSVT, male sex, non-missense variants). This gene-specific threshold is only applied when LMNA is molecularly confirmed.

Mavacamten is FDA-approved specifically for obstructive HCM — the first gene-pathway-targeted heart failure therapy

Mavacamten (Camzyos) inhibits cardiac myosin ATPase activity, reducing hypercontractility in HCM. It is FDA-approved for symptomatic obstructive HCM and produces substantial improvements in LVOT gradient, symptoms, and exercise capacity. Genetic testing confirming HCM-causing sarcomeric variants (MYH7, MYBPC3) supports the diagnosis and may predict mavacamten response. Additionally, the genetic context distinguishes sarcomeric HCM from phenocopies (Fabry disease, amyloidosis, Danon disease) that resemble HCM but require completely different treatment.

Heart Failure Genetic Risk — cardiomyopathy is the leading cause of heart failure in young adults, and approximately 30-50% has a genetic cause where the specific gene determines whether early ICD placement, disease-specific therapy, or family screening is needed.

Heart Failure — Genetic Risk

Standard heart failure guidelines use LVEF <35% for ICD decisions. LMNA patients die at LVEF 40-50%. Gene-specific management saves lives by lowering intervention thresholds for high-risk genotypes.

LMNA-DCM requires ICD at higher LVEF than standard guidelines — molecular diagnosis prevents sudden cardiac death

Mavacamten is FDA-approved specifically for obstructive HCM — the first gene-pathway-targeted heart failure therapy

Others in Cardiovascular

One test. A lifetime of answers.